Article

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL

Author(s):

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center

Michael Wang, MD

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.1

Additionally, when compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.

Patients who have these higher-risk characteristics, the researchers wrote, typically have poor prognosis when receiving standard therapies.

“KTE-X19 pharmacokinetic and pharmacodynamic profiles were generally comparable across lower and high-risk patients consistent with comparable clinical responses with a trend toward increased pro-inflammatory markers in patients with a mutated TP53,” Luhua (Michael) Wang, MD, a professor in the department of lymphoma and myeloma at The University of Texas MD Anderson Cancer Center, said in a pre-recorded presentation. “In addition, the pharmacodynamic profile of KTE-X19 was associated with the efficacy including early MRD status and grade 4 neurotoxicity.”

Results from the primary efficacy analysis of the ZUMA-2 trial demonstrated that patients with relapsed/refractory MCL — who had received 1 to 5 previous therapies — achieved an objective response rate of 93% (67% complete responses) after receiving KTE-X19. The results were generally comparable among patients with high-risk disease.

CAR T-cell levels in the blood were associated with objective response and toxicity.

To compare the pharmacological profile of KTE-X19 in lower- and higher-risk patients within ZUMA-2, Wang and colleagues conducted a comparative analysis and analyzed product attributes, CAR T-cell and serum cytokine levels in the blood, as well as any associations with clinical outcomes.

Additionally, the researchers wanted to characterize the pharmacodynamic profile of patients who achieved MRD-negative status by day 28 and who presented with a grade 4 neurotoxicity.

The study drug demonstrated a minimal bias toward CD8 and effector memory phenotypes, with a median CD4/CD8 ratio of 0.7; median naïve T-cell phenotype of 24.5%; median central memory T-cells of 12.8%; median effector memory T-cells of 24.5% and median effector T-cells of 28.7%.

MRD was analyzed in 29 of the available 68 patients. Of those 29 patients, 83% (19 complete response and 5 partial response) reached MRD negativity one month after receiving KTE-X19.

At one month following KTE-X19 treatment, patients who were MRD-negative had increased median cytokine levels of interferon (INF)-γ, interleukin (IL)-6, IL-15, IL-2, and IL-10. The levels, according to the data, peaked in the serum within 7 days of treatment.

Patients who were MRD negative by the first month after treatment also had increased median peak levels of Granzyme B and soluble programmed death-ligand 1 (PD-L1).

Six patients developed neurologic events that were labelled as grade 4 in severity, including one case of cerebral edema. Three of those patients developed concurrent grade 4 cytokine release syndrome.

This subgroup of patients had higher peak serum levels of INF-γ, tumor necrosis factor alpha (TNF-α), monocyte chemoattractant protein-1, IL-2 and IL-6 than patients without any grade 4 neurologic events.

“Altogether, this pharmacological data supports the concept of CAR T-cell therapy being able to overcome MCL disease with poor risk factors,” concluded Wang.

Wang M, Rossi JM, Munoz J, et al. Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial. Presented at: 2020 ASCO Virtual Scientific Program. Abstract 3023.

<<< 2020 ASCO Virtual Scientific Program

Related Videos
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Manali Kamdar, MD
Ibrahim Aldoss, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Tycel Phillips, MD, MPH
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine